Lipocine announces regulatory guidance on lpcn 1144 in non-cirrhotic nash

Salt lake city, march 1, 2022 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today provided an update from the type c guidance meeting with the u.s. food and drug administration ("fda") regarding the development path for lpcn 1144. lpcn 1144 is targeted for treatment for nonalcoholic steatohepatitis (nash) in non-cirrhotic men.
LPCN Ratings Summary
LPCN Quant Ranking